|
|
|
CytomX Therapeutics and Astellas to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer
“This collaboration with Astellas leverages CytomX’s deep expertise in targeting multiple antibody modalities to the tumor microenvironment,” said Sean McCarthy, D. Phil., President, Chief Executive Officer and Chairman of CytomX. “We are excited about the use of our technology to assist Astellas in unlocking the potential of T-cell engaging bispecifics in the treatment of solid tumors, building on the growing proof of concept we have established for our platform.”
|
|
Agios Provides Update on 2016 Collaboration Agreement with Celgene (Bristol Myers Squib)
“We are grateful to Celgene, and now Bristol Myers Squibb, for their longstanding partnership, which has enabled important research and clinical development focused on the advancement of potential innovative treatment approaches for patients with cancer,” said Jackie Fouse, Ph.D., chief executive officer at Agios. “We are now evolving our relationship to enable both companies to advance our respective priorities with full strategic flexibility.”
|
Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 + Ibrance® (palbociclib) Combination
Dr. Ting XU, Founder, Chairman and CEO of Alphamab Oncology commented, “Through the collaboration with Pfizer, we are on the right track to investigate the combination of KN026 and a CDK4/6 inhibitor for patients with HER2-positive breast cancer as a chemo-free regimen. By combining KN026 with palbociclib , we believe it has the potential to provide more effective treatment options for patients with HER2 positive breast cancer.”
|
|
|
After COVID-19, Roche sets sight on Gram negative superbugs inking a $190.5 million deal with LpxC antibiotic maker Forge Therapeutics
On 25th May 2020, Roche signed a $190.5 million deal with Forge therapeutics (Forge) to license its FG-LpxC LUNG, a novel compound that inhibits Lipid A formation in antibiotic-resistant, Gram-negative bacteria including Pseudomonas aeruginosa.
“We look forward to combining our novel approach and innovative chemistry with Roche's proven drug development and commercialization expertise to provide a truly new class of antibiotic for people suffering from serious antibiotic-resistant infections.”- Zachary Zimmerman, Ph.D., CEO of Forge.
|
|
AstraZeneca and Silence Therapeutics collaborate over a $60 million deal to advance siRNA treatments to multiple organs
AstraZeneca and Silence Therapeutics (Silence) announced a collaboration to advance targeted siRNA treatments developed by the latter into disease areas spanning cardiovascular, renal, metabolic and lung diseases (25th March 2020).
"This collaboration with Silence adds an exciting new modality, siRNA, into our drug discovery toolbox. Importantly we can apply this drug modality across our key therapy areas in cardiovascular, renal and metabolism and respiratory to target novel pathways not amenable to more traditional drug discovery approaches."- Mene Pangalos, EVP BioPharmaceuticals R&D, AstraZeneca.
|
Redpin Therapeutics secures $15.5 million in series A funding for its molecular switch-controlled chemogenetic treatments
Redpin Therapeutics (Redpin, New York), a pre-clinical chemogenetics company, has an interesting gene therapy platform conferring high specificity to target cells.
“We sort of the do the opposite of what has been done in the pharmaceutical industry for decades and decades. Instead of making small molecules for a biologic target or receptor, we pick a drug and then we make a very, very specific receptor for it. As long as these two molecules, the receptor and the small molecule, engage, you will have an effect on the neuron” – Elma Hawkins, CEO, Redpin.
|
|
Click Here for more details on these technologies, mergers and acquisitions
|
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|